Hyperplasia may be treated by using a tumescent, perileukolysis, or excision or laser therapy may be used to remove localized tissue. Treatments may include topical anesthesia or the use of lidocaine.\n
In the colonic mucosa, the proliferating cells are usually crypts that are embedded in a stroma with a thick myofibrous pseudotracheomal layer. The cells have proliferating crypt foci, which sometimes display dysplasia. Hyperplasia with increased crypts and crypt foci is associated with [ulcerative colitis](https://www.withpower.com/clinical-trials/ulcerative-colitis) and other chronic inflammatory diseases. Hyperplasia with crypt foci and increased crypt foci occur with colitis-associated neoplasia. Focal hyperplasia with crypt foci is caused by exposure to radiation, especially ionizing radiation.
Hyperplasia is tissue expansion that typically occurs as a reparative response to injury or excessive cell division. This is a common phenomenon seen in scar tissue formation as an adaptive response to a damaged or destroyed organ which undergoes repair by inflammation.
About 20 million Americans have at least one case of HCM a year - making it the most common cause of heart disease in men.
[A study of patients for which the cause of post-treatment hyperplasia was unknown] concluded that hyperplasia did not respond to treatment and therefore was not curable despite complete removal of all hyperplastic tissues.
XFLO(TacSorb®) systems were successful at immobilizing a portion of the patient's arm in a predictable and reliable manner. XFLO(TacSorb®) systems provided a less than 5% deviation from the mean of the measured displacement from the treatment arm for the treatment zone and provided a mean deviation of - 4.0 mm, with an average measured displacement of -4.7 mm.
There are no treatments currently available for treating hyperplasia. Many treatments currently use oncology medications, such as cisplatinum and fludarabine. These medications can cause many side effects, including fatigue.
As long as the hyperplasia is limited to the esophagus, stomach or small intestine, it may be manageable with surgery or with or without esomeprazole. Clinical trials tailored to hyperplasia should only be considered in patients who have an esophageal, gastric or small intestinal component to their disease.
The xflo is a safe and useful device used for the treatment of acute breast cysts. The main advantages over traditional silicone devices are the lower incidence of granuloma, lower risk of migration and implant rupture, lower incidence of capsular contracture, and improved outcomes in case of capsular contracture.
There is no evidence that this Xflo expander system promotes tumour formation in vivo or in an animal model. There is also no evidence of any difference between Xflo and another expander system, the Arcella system, because of how it promotes tumour formation in vivo or in an animal model. Therefore, we do not recommend the Xflo expander system for the correction of congenital hypertrophy or edema, nor do we recommend it be used as a filling system in plastic surgery.